Restless Legs Syndrome Pipeline Review, H2 2018 - Therapeutic Assessment of 6 Companies - ResearchAndMarkets.com

September 26, 2018

DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Restless Legs Syndrome - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Restless Legs Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 1 and 3 respectively.

Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Report Coverage Restless Legs Syndrome - Overview Restless Legs Syndrome - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Restless Legs Syndrome - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Restless Legs Syndrome - Companies Involved in Therapeutics Development Bioprojet SCR Galenica Ltd Hisamitsu Pharmaceutical Co Inc Merz Pharma GmbH & Co KgaA Omeros Corp Serina Therapeutics Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/v7srll/restless_legs?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180926006027/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/26/2018 04:39 PM/DISC: 09/26/2018 04:39 PM


Update hourly